The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Identification of the Dynamic Compaction Process of Asphalt Mixture Rollers

Представлена имитационная модель уплотняемой смеси с применением программы MATLAB/ Simulink, системы компьютерного моделирования рабочего процесса вибрационного катка. Приведены зависимости контактного давления вальца, абсолютной деформации смеси, ускорения изменения деформации смеси от времени контакта вальца катка с уплотняемой смесью. Получены графические зависимости результатов обработки данных имитационного моделирования на основе регрессионного анализа средствами MS Excel. Результаты работы могут использоваться при идентификации параметров асфальтобетонной смеси и параметров вибрации для целей автоматизации процесса уплотнения и соответствующего выбора датчиков информации о состоянии уплотняемой смеси.Work is devoted to the identification of dynamic system compaction process of asphalt concrete mixtures vibrating rollers. Presented a simulation model of the sealed environment, using the program MATLAB / Simulink, a system of computer simulation of the vibratory roller. Shows the dependence of the contact pressure roller, the absolute strain the mixture to accelerate change in strain environment from the time of contact with roller compacted mixture. Graphic shows results depending on data simulation based on regression analysis by means of MS Excel. The results can be used for the purposes of identifying the parameters of the environment and the vibration parameters for automation purposes, to select the sensors about the state of the environment

Identification of the Dynamic Compaction Process of Asphalt Mixture Rollers

Представлена имитационная модель уплотняемой смеси с применением программы MATLAB/ Simulink, системы компьютерного моделирования рабочего процесса вибрационного катка. Приведены зависимости контактного давления вальца, абсолютной деформации смеси, ускорения изменения деформации смеси от времени контакта вальца катка с уплотняемой смесью. Получены графические зависимости результатов обработки данных имитационного моделирования на основе регрессионного анализа средствами MS Excel. Результаты работы могут использоваться при идентификации параметров асфальтобетонной смеси и параметров вибрации для целей автоматизации процесса уплотнения и соответствующего выбора датчиков информации о состоянии уплотняемой смеси.Work is devoted to the identification of dynamic system compaction process of asphalt concrete mixtures vibrating rollers. Presented a simulation model of the sealed environment, using the program MATLAB / Simulink, a system of computer simulation of the vibratory roller. Shows the dependence of the contact pressure roller, the absolute strain the mixture to accelerate change in strain environment from the time of contact with roller compacted mixture. Graphic shows results depending on data simulation based on regression analysis by means of MS Excel. The results can be used for the purposes of identifying the parameters of the environment and the vibration parameters for automation purposes, to select the sensors about the state of the environment

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701